During the past decade, The Office of Bridget Bellingar, DO conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 3 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "The Office of Bridget Bellingar, DO" are "Cardiovascular Disease" (2 trials), "Hypertension" (2 trials) and "Hypercholesterolemia" (1 trials). Many other conditions were trialed in "The Office of Bridget Bellingar, DO" in a lesser frequency.

Most popular intervention types in "The Office of Bridget Bellingar, DO" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Darusentan" (2 trials), "Guanfacine" (2 trials), "Placebo" (2 trials), "bococizumab (PF-04950615)" (2 trials) and "200mg PF-04950615 (RN316)" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Office of Bridget Bellingar, DO" are 5 trials for "All" genders.

Currently, there are NaN active trials in "The Office of Bridget Bellingar, DO". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in The Office of Bridget Bellingar, DO, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in The Office of Bridget Bellingar, DO, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".